Skip to main content
Premium Trial:

Request an Annual Quote

Myconostica Gets OK to Sell Fungal Dx in Canada

NEW YORK (GenomeWeb News) – Medical diagnostic company Myconostica said yesterday that it has received a license from Health Canada to sell its Aspergillus molecular diagnostic test in Canada.

Myconostica's MycAssay Aspergillus detects Aspergillus DNA in lower respiratory tract samples. Results of the test aid physicians in diagnosing immunocompromised patients suspected of having an infection caused by the fungus.

When MycAssay is used in conjunction with Myconostica's extraction system, MycXtra, a result can be obtained within three hours of sample receipt, the company said.

In conjunction with the announcement, Myconostica, based in Manchester, UK, also said that it has signed an agreement with Inverness Medical Canada, a subsidiary of Inverness Medical Innovations, to exclusively distribute Myconostica's products in Canada.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.